Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Cash from Financing Activities came in at $193.8 million in Q1 2026, up 4548.26% year-on-year from $4.2 million in Q1 2025, and up 164.42% quarter-over-quarter from $73.3 million in Q4 2025.
Scholar Rock Holding (SRRK) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $193.8 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 4548.26% year-over-year to $193.8 million in Q1 2026; TTM through Mar 2026 was $418.0 million, a 19.2% increase from a year earlier, with the FY2025 full-year figure at $228.4 million, down 35.3% from the prior year.
- Cash from Financing Activities improved to $193.8 million in Q1 2026 per SRRK's latest filing, from $73.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $346.4 million in Q4 2024 and bottomed at -$970000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $4.7 million (2023), against an average of $63.1 million.
- Across the five-year window, Cash from Financing Activities plunged 123.66% in 2022 and jumped 86929.52% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$970000.0 in 2022, then soared by 10051.44% to $96.5 million in 2023, then jumped by 258.82% to $346.4 million in 2024, then sank by 78.84% to $73.3 million in 2025, then surged by 164.42% to $193.8 million in 2026.
- Per Business Quant, the three latest SRRK Cash from Financing Activities figures stand at $193.8 million (Q1 2026), $73.3 million (Q4 2025), and $144.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | 193.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193.79 Mn |
| Mar 31, 2026 | 193.79 Mn |
| Dec 31, 2025 | 73.29 Mn |
| Dec 31, 2025 | 73.29 Mn |
| Sep 30, 2025 | 144.47 Mn |
| Sep 30, 2025 | 144.47 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 4.17 Mn |
| Mar 31, 2025 | 4.17 Mn |
| Dec 31, 2024 | 346.37 Mn |
| Dec 31, 2024 | 346.37 Mn |
| Sep 30, 2024 | 166,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | 6.53 Mn |
| Mar 31, 2024 | 6.53 Mn |
| Dec 31, 2023 | 96.53 Mn |
| Dec 31, 2023 | 96.53 Mn |